This $717,871 federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) aims to develop an epigenomic liquid biopsy screening tool for early detection and prediction of preterm birth, preeclampsia, and intrauterine growth restriction.
The overarching goal is to leverage cell-free DNA analysis of maternal plasma to identify methylation signatures indicative of pathological changes underlying these pregnancy complications. The research will be conducted primarily by the Magee-Womens Research Institute and Foundation, a non-profit medical research organization, with a subaward to the University of Pittsburgh to support data analysis and genomic sequencing. The 5-year project period runs from August 2024 to July 2029.
Generated 3/25/25, 4:35 AM